DNB Asset Management Sells Eli Lilly Shares

Institutional investor reduces stake in pharmaceutical giant

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

DNB Asset Management AS, an institutional investor, decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 5.9% during the third quarter. The firm now owns 333,993 shares of the company's stock, valued at $254,837,000, after selling 20,847 shares.

Why it matters

This transaction provides insight into the investment strategy of DNB Asset Management, a major institutional investor. Changes in large shareholders' positions can impact a company's stock price and influence market sentiment.

The details

According to a disclosure with the Securities & Exchange Commission, DNB Asset Management AS sold 20,847 shares of Eli Lilly and Company during the third quarter. The firm now owns a total of 333,993 shares, comprising about 1.0% of its investment portfolio.

  • DNB Asset Management AS sold the shares during the third quarter of the year.

The players

DNB Asset Management AS

An institutional investor and asset management firm.

Eli Lilly and Company

A global pharmaceutical company headquartered in Indianapolis, Indiana.

Got photos? Submit your photos here. ›

The takeaway

This transaction reflects DNB Asset Management's portfolio adjustments, which may be driven by various factors such as market conditions, investment strategy changes, or rebalancing. Investors will likely monitor Eli Lilly's stock performance and any further changes in major institutional holdings.